Everolimus, Sirolimus Generally Safe for Epilepsy in Tuberous Sclerosis Complex
Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.
Tuberculosis
Afinitor Disperz Approved to Treat TSC-Associated Partial-Onset Seizures
The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.
Vigabatrin Beneficial for Focal Seizures in Tuberous Sclerosis Complex
Vigabatrin may be an effective option for patients with seizures due to tuberous sclerosis who do not respond to other anti-seizure treatments.
Factors Predictive of Everolimus Efficacy in Tuberous Sclerosis Complex
Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.
Everolimus Safe, Effective for Reduction of Seizures in Tuberous Sclerosis Complex
The EXIST-3 trial is the first phase 3 study to evaluate the use of EVE for the adjunctive treatment of seizures in TSC.
Everolimus Effective in Reducing Seizures in Tuberous Sclerosis Complex
The drug, which is indicated to treat certain types of cancer, is effective at reducing seizures in TSC when used as adjunctive therapy.
Next post in AAN 2016 Coverage
